Melissa B. Epperly - 12 Jun 2023 Form 4 Insider Report for Kinnate Biopharma Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 12 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2023, 18:26:25 UTC
Prior SEC filing: 14 Feb 2023
Next SEC filing: 16 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Mark A. Meltz, as attorney-in-fact

Key filing fact

Melissa B. Epperly filed Form 4 for Kinnate Biopharma Inc. on 13 Jun 2023.

Key facts

This page summarizes Melissa B. Epperly's Form 4 filing for Kinnate Biopharma Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Jun 2023, 18:26.

Change

Previous filing in this sequence was filed on 14 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNTE transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 12 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $3.48
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 12, 2023 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date.